The value of nabufine combined with dexmedetomidine in painless ultrasound bronchoscopy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000029667

Enrollment

Unknown

Registered

2020-02-09

Start date

2020-03-01

Completion date

Unknown

Last updated

2020-02-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary disease

Interventions

experimental group:Nabufine combined with Dexmedetomidine

control group:Sufentanil

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. ASA level I-III agreed to participate in the test and signed the written informed consent; 2. Age 18-65 years old, no long-term use of strong opioid drug history; 3. No neuromuscular disease, serious hepatorenal disease, cardiovascular disease (severe bradycardia), cardiac dysfunction, history of bronchial asthma and hypercapnia before operation; 4. Body mass index (BMI) 18-27.

Exclusion criteria

Exclusion criteria: 1. Patients with certain allergic reactions to the drugs used in this study, such as naborphine, dexmedetomidine, sufentanil and their components; 2. Acute respiratory infection; 3. Suspected difficult airway such as snoring, limited head and neck movement and neck operation history; 4. Participants in other clinical trials; 5. Patients with chronic pain, neurological or mental illness, long-term use of sedatives and analgesics, and long-term use of antipsychotic drugs.

Design outcomes

Primary

Measure	Time frame
VAS score;Ramsay score;Anesthetic effect classification;MMSE score;S100;	—

Countries

China

Contacts

Public ContactNianping Chen

Affiliated Hospital of Shaoxing University

sxcnp@126.com+86 13336801869

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026